Shares of Conagra Brands, Inc. (NYSE: CAG) were down on Thursday. The stock has dropped 13% year-to-date. The company is set to report fourth quarter 2023 earnings results on Thursday, July 13, before market open. Here’s a look at what to expect from the earnings report:
Revenue
Analysts are projecting revenue of $3 billion for the fourth quarter of 2023, which would represent a growth of 3% from the same period last year. In the third quarter of 2023, net sales increased nearly 6% year-over-year to $3.1 billion.
Earnings
The consensus estimate is for EPS of $0.59 for Q4 2023, which is down compared to EPS of $0.65 reported in the year-ago quarter. In Q3 2023, adjusted EPS increased 31% to $0.76.
Points to note
In Q3, Conagra’s sales benefited from a favorable price/mix, fueled by its inflation-driven pricing actions. However, the elasticity impact from these pricing actions negatively impacted volume which fell 9% in the quarter. The fourth quarter could see a similar trend.
The company saw sales growth across all its segments with an improvement in price/mix offset by volume declines. Conagra saw strength in its snacks and staples categories with gains in meat snacks and microwave popcorn as well as sauces and marinades. Gains in frozen sides, breakfast sausage, and single-serve meals drove strength in the frozen segment. The company also gained share in plant-based protein. A continuation of these trends could benefit results in the fourth quarter.
Strong growth in the Foodservice segment is another positive point for the company. In Q3, sales in Foodservice grew over 17% year-over-year. This momentum is likely to have continued in the fourth quarter benefiting overall results.
Conagra’s favorable price-mix and supply chain productivity initiatives helped drive margin improvement during the third quarter but these benefits were partly offset by inflationary pressures. The company expects gross inflation of approx. 10% for FY2023.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on